Stern, David F - Yale University - Biological & Biomedical Sciences

个人简介

Dr. Stern earned a BS in Biology at MIT in 1976. He received a PhD in Biology in 1983 at University of California, San Diego, and the Salk Institute with S.I.T. Kennedy and Bart Sefton for dissertation research that elucidated the coronavirus lytic cycle. Dr. Stern returned to R.A. Weinberg’s lab at the MIT Cancer Center and Whitehead Institute for Biomedical Research in 1983. There, Dr. Stern’s postdoctoral work pioneered analysis of neu/ErbB2/HER2, an important human oncogene. As a Yale Pathology faculty member since 1988, Dr. Stern’s research has focused on the roles of eleven growth factors and four receptors of the EGF family in malignant transformation, especially in breast cancer, and he has also made significant contributions to the understanding of DNA damage response signaling pathways. Dr. Stern’s current work in breast cancer and melanoma includes developing approaches to countering rapid resistance to anti-cancer agents that target cancer signaling pathways. Dr. Stern is active in cancer training at Yale and in the Yale Cancer Center scientific leadership. He is co-leader of the Signal Transduction Research Program and Associate Director of Shared Resources of the Yale Cancer Center. PhD University of California, San Diego (1983) BS Massachusetts Institute of Technology, Biology (1976) Postdoctoral Fellow Whitehead Institute for Biomedical Research at Mass. Institute of Technology

研究领域

Breast Neoplasms; DNA Damage; Melanoma; Neoplasms; Pathology; Signal Transduction

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Complete list of published work in My Bibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/david.stern.1/bibliography/40866180/public/?sort=date&direction=ascending Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake Jonathan W. Haskins, Shannon Zhang, Robert E. Means, Joanne K. Kelleher, Gary W. Cline, Alberto Canfrán-Duque, Yajaira Suárez, and David F. Stern. Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake. 2015 Science Signaling 8:ra111 The Broad Spectrum Receptor Tyrosine Kinase Inhibitor Dovitinib Suppresses Growth of BRAF Mutant Melanoma Cells in Combination with Other Signaling Pathway Inhibitors. CG Langdon MH, JTPlatt, P Iyidogan, R Mamillapalli, AB Koo, M Klein, Z Liu, MW Bosenberg, and DF Stern. The Broad Spectrum Receptor Tyrosine Kinase Inhibitor Dovitinib Suppresses Growth of BRAF Mutant Melanoma Cells in Combination with Other Signaling Pathway Inhibitors. Pigment Cell Melanoma Res. 2015; Apr 9. doi: 10.1111/pcmr.12376. [Epub ahead of print] PMID: 25854919 Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Haskins JW, Nguyen DX, Stern DF. Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Sci Signal. 2014;7(355):ra116 PMID: 25492965. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveal isoform-specific roles in mammary gland development and carcinogenesis. V. B. Wali, M. Gilmore-Hebert, R. Mamillapalli, J. W. Haskins, K. J. Kurppa, K. Elenius, C. J. Booth, D. F. Stern, Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveal isoform-specific roles in mammary gland development and carcinogenesis. Breast Cancer Res 16, 501 (2014); published online EpubDec 17 (10.1186/s13058-014-0501-z). Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkappaB) pathway. Colavito SA, Zou MR, Yan Q, Nguyen DX, Stern DF. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkappaB) pathway. Breast Cancer Res. 2014;16(5):444. PMCID: PMC4303124. Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells. Wali VB, Haskins JW, Gilmore-Hebert M, Platt JT, Liu Z, Stern DF. Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells. Mol Cancer Res. 2014;12(8):1140-55. PMCID: PMC4303208. EGF Receptor activates MET through MAP kinases to enhance non-small cell lung carcinoma invasion and brain metastasis. EGF Receptor activates MET through MAP kinases to enhance non-small cell lung carcinoma invasion and brain metastasis. Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF. Cancer Res. 2013 Jun 21. [Epub ahead of print] Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method. Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF. Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method. PLoS One. 2013;8(11):e79901. PMCID: PMC3836903 MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF. Pigment Cell Melanoma Res. 2013 Jul;26(4):527-41. doi: 10.1111/pcmr.12110. Epub 2013 May 21. PMID: 23617806 [PubMed - in process] Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Cancer Discov. 2013 Jan;3(1):52-67. doi: 10.1158/2159-8290.CD-12-0408. Epub 2012 Dec 13. PMID: 23239741 [PubMed - indexed for MEDLINE] Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.